A recently described AML entity, “AML with pDC differentiation” [50], demonstrated frequent RUNX1 mutations and expression of lymphoid antigens, comparable to RUNX1mut BP-CML. Here, RUNX1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.